miragen
therapeutics
inc
announces
acquisition
viridian
therapeutics
inc
acquisition
includes
clinical
stage
monoclonal
antibody
intended
treatment
thyroid
eye
disease
ted
company
plans
use
private
placement
financing
proceeds
million
advance
multiple
compounds
phase
proof
concept
studies
ted
expand
orphan
disease
pipeline
conference
call
webcast
today
edt
boulder
waltham
globe
newswire
miragen
therapeutics
miragen
nasdaq
mgen
today
announced
completed
acquisition
viridian
therapeutics
viridian
privately
held
biotechnology
company
focused
advancing
new
treatments
patients
diseases
underserved
today
therapies
concurrent
acquisition
viridian
miragen
entered
definitive
agreement
sale
series
convertible
preferred
stock
series
preferred
stock
private
placement
group
institutional
accredited
investors
led
fairmount
funds
management
llc
fairmount
funds
participation
venrock
healthcare
capital
partners
bvf
partners
cormorant
asset
management
perceptive
advisors
wellington
management
ally
bridge
group
logos
capital
surveyor
capital
citadel
company
commodore
capital
ridgeback
capital
well
additional
undisclosed
institutional
investors
private
placement
expected
result
gross
proceeds
miragen
approximately
million
deducting
placement
agent
offering
expenses
proceeds
private
placement
intended
used
primarily
advance
clinical
studies
growth
receptor
monoclonal
antibody
mab
development
thyroid
eye
disease
ted
debilitating
condition
cause
bulging
eyes
proptosis
well
double
vision
potential
blindness
thorough
evaluation
strategic
alternatives
board
directors
miragen
believes
acquisition
represents
value
creation
opportunity
miragen
stockholders
sincere
thanks
appreciation
board
members
management
team
past
present
along
investors
support
commitment
said
jeffrey
hatfield
chairman
board
directors
miragen
excited
potential
become
meaningful
treatment
option
patients
living
miragen
lead
candidate
studied
potential
treatment
patients
ted
oncology
patients
previously
treated
antibody
us
eu
studies
name
enabling
understanding
pharmacokinetic
pharmacodynamic
profile
well
safety
tolerability
pending
feedback
regulatory
authorities
miragen
expects
initiate
phase
clinical
trial
ted
worldwide
rights
develop
commercialize
indications
use
radiopharmaceuticals
including
treatment
ted
exclusively
licensed
viridian
immunogen
inc
terms
agreement
immunogen
received
upfront
payment
eligible
additional
developmental
milestones
royalty
payments
parallel
development
viridian
initiated
program
seeks
improve
antibodies
incorporating
extension
technology
reduce
dose
required
achieve
full
efficacy
ted
patients
enhance
solubility
achieve
lowest
possible
injection
volume
program
advancing
rapidly
miragen
expects
file
investigational
new
drug
application
contingent
value
right
connection
transactions
announced
today
contingent
value
right
cvr
expected
distributed
holders
miragen
common
stock
within
next
days
holders
cvr
entitled
receive
certain
payments
proceeds
received
miragen
related
disposition
legacy
assets
period
five
years
following
closing
transaction
miragen
actively
conducting
outreach
find
partner
new
enterprises
legacy
programs
management
organization
current
miragen
management
team
including
lee
rauch
chief
executive
officer
jason
leverone
chief
financial
officer
diana
escolar
md
ffan
chief
medical
officer
expanded
appointment
jonathan
violin
phd
ceo
viridian
president
chief
operating
officer
miragen
vahe
bedian
phd
chief
scientific
officer
viridian
cso
miragen
conjunction
transaction
miragen
board
members
include
jeffrey
hatfield
chairman
board
directors
miragen
peter
harwin
managing
member
fairmount
funds
tomas
kiselak
managing
member
fairmount
funds
current
miragen
board
members
arlene
morris
ceo
willow
advisors
llc
lee
rauch
ceo
miragen
joe
turner
board
directors
audit
chair
miragen
transactions
acquisition
viridian
structured
transaction
whereby
viridian
outstanding
equity
interests
exchanged
combination
shares
miragen
common
stock
shares
series
preferred
stock
concurrently
acquisition
viridian
miragen
entered
definitive
agreements
pipe
investment
existing
new
investors
raise
million
investors
issued
shares
series
preferred
stock
price
per
share
per
share
basis
pipe
offering
expected
close
october
subject
stockholder
approval
share
series
preferred
stock
option
holder
convert
shares
common
stock
subject
certain
beneficial
ownership
limitations
set
holder
pro
forma
basis
based
upon
number
shares
miragen
common
stock
preferred
stock
issued
acquisition
concurrent
financing
miragen
equity
holders
immediately
prior
acquisition
approximately
miragen
basis
immediately
transactions
acquisition
approved
board
directors
miragen
board
directors
equity
holders
viridian
closing
transactions
subject
approval
miragen
stockholders
ladenburg
thalmann
serving
exclusive
financial
advisor
miragen
cooley
llp
serving
legal
counsel
miragen
wedbush
pacgrow
serving
exclusive
strategic
advisor
viridian
gibson
dunn
crutcher
llp
serving
legal
counsel
viridian
jefferies
llc
acting
lead
placement
agent
private
placement
jmp
securities
llc
acting
agent
wilmer
cutler
pickering
hale
dorr
llp
serving
legal
counsel
placement
agents
completion
acquisition
private
placement
financing
miragen
expected
pro
forma
cash
hand
approximately
million
cash
runway
additional
details
available
updated
corporate
presentation
found
online
conference
call
webcast
details
miragen
host
conference
call
webcast
october
edt
discuss
acquisition
access
call
please
dial
international
provide
conference
id
access
webcast
please
go
http
information
acquisition
please
visit
investor
section
miragen
website
miragen
therapeutics
miragen
therapeutics
biotechnology
company
advancing
new
treatments
patients
diseases
underserved
today
therapies
miragen
advanced
program
monoclonal
antibody
development
thyroid
eye
disease
ted
miragen
headquartered
boulder
research
development
operations
waltham
mass
follow
miragen
therapeutics
social
media
miragenrx
linkedin
forward
looking
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
including
limited
statements
regarding
uses
proceeds
projected
cash
runways
future
product
development
plans
stockholder
approval
conversion
rights
series
preferred
stock
future
payouts
cvr
use
words
limited
anticipate
believe
continue
could
estimate
expect
intend
may
might
plan
potential
predict
project
target
would
similar
words
expressions
intended
identify
statements
statements
neither
historical
facts
assurances
future
performance
instead
based
current
beliefs
expectations
assumptions
regarding
future
business
future
plans
strategies
clinical
results
future
conditions
new
risks
uncertainties
may
emerge
time
time
possible
predict
risks
uncertainties
representations
warranties
expressed
implied
made
accuracy
statements
may
actually
achieve
forecasts
disclosed
statements
place
undue
reliance
statements
statements
subject
number
material
risks
uncertainties
including
limited
set
forth
caption
risk
factors
miragen
recent
annual
report
form
filed
sec
well
discussions
potential
risks
uncertainties
important
factors
subsequent
filings
sec
statement
speaks
date
made
neither
affiliates
advisors
representatives
undertake
obligation
publicly
update
revise
statement
whether
result
new
information
future
events
otherwise
except
required
law
statements
relied
upon
representing
views
date
subsequent
date
hereof
investor
relations
contact
dan
ferry
lifesci
advisors
daniel
media
contact
darby
pearson
verge
scientific
communications
dpearson
